Revenue declined by 0.95 % YoY to Rs. 209.3 crs for 4Q 09, whereas it increased 10.12% to Rs. 774.4 crs in FY 2009.

Operating profit declined by 8.94% y?o?y to Rs. 59.7 crs for 4Q 09, while it increased 26.2% to Rs. 182.0 crs for the year driven by decline in raw material costs. Raw material costs as a percentage of revenue declined from 52.3% in FY 2008 to 49.5% in FY 2009

Depreciation increased by 45.3% in 4Q 09. Whereas in FY 2009 it increased by 47.7% to Rs. 8.2 crs.

Nirmal Bang Research has maintained ‘Sell’ rating on Reliance Capital stock to achieve a target that lies between Rs 475-430.

According to research report, investors can sell the stock with a strict stop loss of Rs 517.

Today (April 23), the stock opened at Rs 512.25 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 41.65 and 12.05 respectively. The share price has seen a 52-week high of Rs 1620 and a low of Rs 274.20 on BSE.

Nirmal Bang is of the view that investors should sell the stock today in order to avoid loss.

Nirmal Bang, one of the leading equity research-cum-broking house, is of the view that investors can sell BHEL with a target price of Rs 1505-1440.

According to experts at Nirmal Bang, interested traders can sell the stock below its 13-day EMA of 1575, with a stop loss of Rs 1630.

Nirmal Bang Research is bullish on Moser Baer (India) Limited and maintained ‘Buy’ rating on the stock to achieve a target between Rs 69-78 within 1-5 days.

Traders can buy the stock on dips with a stop loss of Rs 58.

Shares of the company, on Wednesday (April 22), closed at Rs 62.90 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 201.30 and a low of Rs 41.10 on BSE.

According to Nirmal Bang report, the structure looks very positive, so buy the stock and hold, if it maintains above Rs 67, a big move is expected.

Dr Reddy's Laboratories Ltd, an emerging global pharmaceutical company, has finally launched RedisparT (Doxercalci) in Indian market.

According to a press release, RedisparT is the first pro-vitamin D2 to be available in the country, which is used in the treatment of secondary hyperparathyroidism (SHPT) due to chronic kidney disease.

In addition, the drug is also used to maintain the parathyroid hormone (PTH) and calcium levels in the body in chronic kidney disease patients.